Skip to main content Back to Top
Advertisement

11/15/2019

Anagrelide Hydrochloride Capsules

Products Affected - Description

    • Agrylin oral capsule, Shire (Takeda), 0.5 mg, bottle, 100 count, NDC 54092-0063-01
    • Anagrelide Hydrochloride oral capsule, Teva, 0.5 mg, bottle, 100 count, NDC 00172-5241-60
    • Anagrelide Hydrochloride oral capsule, Teva, 1 mg, bottle, 100 count, NDC 00172-5240-60
    • Anagrelide Hydrochloride oral capsule, Torrent, 0.5 mg, bottle, 100 count, NDC 13668-0453-01

Reason for the Shortage

    • Shire (Takeda) did not provide a reason for the shortage.
    • Teva did not provide a reason for the shortage.
    • Torrent is working on relaunching anagrelide 0.5 mg capsules.

Available Products

    • Anagrelide Hydrochloride oral capsule, Torrent, 1 mg, bottle, 100 count, NDC 13668-0462-01

Estimated Resupply Dates

    • Shire (Takeda) has Agrylin 0.5 mg capsules available in limited supply. Shire estimates Agrylin will return to full supply in January 2020.
    • Teva has anagrelide 0.5 mg and 1 mg capsules on back order and the company estimates a release date in early- to mid-January 2020.
    • Torrent has anagrelide 0.5 mg capsules unavailable and the company cannot estimate a relaunch date.

Updated

Created November 15, 2019 by Leslie Jensen, PharmD, Drug Information Specialist. © 2019, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins